Cash from Operations (Annual) Chart

View Cash from Operations (Annual) for NVAX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Annual) Chart
Start Trial

Historical Cash from Operations (Annual) Data

View and export this data back to 1995. Start Trial.
Date Value
December 31, 2025 -244.64M
December 31, 2024 -87.26M
December 31, 2023 -717.56M
December 31, 2022 -415.94M
December 31, 2021 322.95M
December 31, 2020 -42.54M
December 31, 2019 -136.62M
December 31, 2018 -184.82M
December 31, 2017 -136.62M
December 31, 2016 -258.77M
December 31, 2015 -89.89M
December 31, 2014 -68.13M
December 31, 2013 -44.93M
December 31, 2012 -18.23M
December 31, 2011 -23.63M
December 31, 2010 -32.85M
Date Value
December 31, 2009 -32.83M
December 31, 2008 -24.31M
December 31, 2007 -26.74M
December 31, 2006 -14.81M
December 31, 2005 -5.809M
December 31, 2004 -30.10M
December 31, 2003 -17.55M
December 31, 2002 -21.07M
December 31, 2001 -4.566M
December 31, 2000 -10.04M
December 31, 1999 -3.70M
December 31, 1998 -3.624M
December 31, 1997 -4.245M
December 31, 1996 -3.651M
December 31, 1995 -6.261M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Annual) Range, Past 5 Years

View Cash from Operations (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Annual) Benchmarks

View Cash from Operations (Annual) Benchmarks
Start Trial
Moderna, Inc. -1.873B
Merck & Co., Inc. 16.47B
Pfizer Inc. 11.70B
Recursion Pharmaceuticals, Inc. -371.81M
Agenus, Inc. -77.20M